Lgr5 expression is a valuable prognostic factor for colorectal cancer: Evidence from a meta-analysis

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Jiang, Yangyan ^a   Li, Wenlu ^b   He, Xin ^a   Zhang, Hongbo ^c   Jiang, Fangzhen ^a   Chen, Zhigang ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c Third People s Hospital   (China)

Author keywords

Clinical pathological differences; Colorectal cancer; Lgr5; Meta analysis; Prognostic value

Indexed keywords

BIOLOGICAL MARKER; FLUOROURACIL; G PROTEIN COUPLED RECEPTOR; LEUCINE RICH REPEAT CONTAINING G PROTEIN COUPLED RECEPTOR 5; UNCLASSIFIED DRUG; LGR5 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; DIAGNOSTIC VALUE; DISTANT METASTASIS; HUMAN; INFORMATION RETRIEVAL; LYMPH NODE METASTASIS; MEDLINE; META ANALYSIS (TOPIC); PROTEIN EXPRESSION; RELIABILITY; SCORING SYSTEM; SENSITIVITY ANALYSIS; TUMOR INVASION; WANFANG DATABASE; WEB OF SCIENCE; BIOSYNTHESIS; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; META ANALYSIS; PATHOLOGY; PROGNOSIS;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84953881173     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1986-2     Document Type: Article

References (34)

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104-17.
2. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2449-60.
3. Hodgson DC, Fuchs CS, Ayanian JZ. Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst. 2001;93(7):501-15.
4. Aranha O. Benson 3rd AB. Adjuvant therapy for colon cancer. Curr Gastroenterol Rep. 2007;9(5):415-21.
5. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol. 2007;18(5):460-6.
6. Rich JN, Bao S. Chemotherapy and cancer stem cells. Cell Stem Cell. 2007;1(4):353-5.
7. Fulda S, Pervaiz S. Apoptosis signaling in cancer stem cells. Int J Biochem Cell Biol. 2010;42(1):31-8.
8. Coco C, Zannoni GF, Caredda E, Sioletic S, Boninsegna A, Migaldi M, et al. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. J Exp Clin Cancer Res. 2012;31:71.
9. Zhang SS, Han ZP, Jing YY, Tao SF, Li TJ, Wang H, et al. CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med. 2012;10:85.
10. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106-10.
11. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2006;445(7123):111-5.
12. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118(6):2111-20.
13. Becker L, Huang Q, Mashimo H. Immunostaining of Lgr5, an intestinal stem cell marker, in normal and premalignant human gastrointestinal tissue. Scientific World Journal. 2008;8:1168-76.
14. Hsu HC, Liu YS, Tseng KC, Hsu CL, Liang Y, Yang TS, et al. Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer. Int J Colorectal Dis. 2013;28(11):1535-46.
15. Yamamoto Y, Sakamoto M, Fujii G, Tsuiji H, Kenetaka K, Asaka M, et al. Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology. 2003;37(3):528-33.
16. McClanahan T, Koseoglu S, Smith K, Grein J, Gustafson E, Black S, et al. Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors. Cancer Biol Ther. 2006;5(4):419-26.
17. Uchida H, Yamazaki K, Fukuma M, Yamada T, Hayashida T, Hasegawa H, et al. Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancer. Cancer Sci. 2010;101(7):1731-7.
18. Tanese K, Fukuma M, Yamada T, Mori T, Yoshikawa T, Watanabe W, et al. G-protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation. Am J Pathol. 2008;173(3):835-43.
19. Ziskin JL, Dunlap D, Yaylaoglu M, Fodor IK, Forrest WF, Patel R, et al. In situ validation of an intestinal stem cell signature in colorectal cancer. Gut. 2013;62(7):1012-23.
20. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815-34.
21. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335-71.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
23. Wu XS, Xi HQ, Chen L. Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival. World J Surg Oncol. 2012;10:244.
24. Saigusa S, Inoue Y, Tanaka K, Toiyama Y, Matsushita K, Kawamura M, et al. Clinical significance of LGR5 and CD44 expression in locally advanced rectal cancer after preoperative chemoradiotherapy. Int J Oncol. 2012;41(5):1643-52.
25. Valladares-Ayerbes M, Blanco-Calvo M, Reboredo M, Lorenzo-Patino MJ, Iglesias-Diaz P, Haz M, et al. Evaluation of the Adenocarcinoma-Associated Gene AGR2 and the Intestinal Stem Cell Marker LGR5 as Biomarkers in Colorectal Cancer. Int J Mol Sci. 2012;13(4):4367-87.
26. Takahashi H, Ishii H, Nishida N, Takemasa I, Mizushima T, Ikeda M, et al. Significance of Lgr5(+ve) cancer stem cells in the colon and rectum. Ann Surg Oncol. 2011;18(4):1166-74.
27. Takeda K, Kinoshita I, Shimizu Y, Matsuno Y, Shichinohe T, Dosaka-Akita H. Expression of LGR5, an intestinal stem cell marker, during each stage of colorectal tumorigenesis. Anticancer Res. 2011;31(1):263-70.
28. Peng CLL, Liang Y, Hu JJ, Wang J, Jiang B, Wang XY. Higher expression of Lgr5 predicts poor prognosis in human colorectal cancer. Modern Digestion Intervention. 2010;15(5):284-7.
29. WG Bao YC. Detection of cancer stem marker, Lgr5, in colorectal cancer. Lin Chuang Jian Yan Za Zhi. 2012;30(9):691-3.
30. Gao FJ, Chen JY, Wu HY, Shi J, Chen M, Fan XS, et al. Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancer. Int J Clin Exp Pathol. 2014;7(4):1572-9.
31. He S, Zhou H, Zhu X, Hu S, Fei M, Wan D, et al. Expression of Lgr5, a marker of intestinal stem cells, in colorectal cancer and its clinicopathological significance. Biomed Pharmacother. 2014;68(5):507-13.
32. Liu Z, Dai W, Jiang L, Cheng Y. Over-expression of LGR5 correlates with poor survival of colon cancer in mice as well as in patients. Neoplasma. 2014;61(2):177-85.
33. Van der Flier LG, Sabates-Bellver J, Oving I, Haegebarth A, De Palo M, Anti M, et al. The Intestinal Wnt/TCF Signature. Gastroenterology. 2007;132(2):628-32.
34. Segditsas S, Sieber O, Deheragoda M, East P, Rowan A, Jeffery R, et al. Putative direct and indirect Wnt targets identified through consistent gene expression changes in APC-mutant intestinal adenomas from humans and mice. Hum Mol Genet. 2008;17(24):3864-75.